Your browser (Internet Explorer 7 or lower) is out of date. It has known security flaws and may not display all features of this and other websites. Learn how to update your browser.

X

Navigate / search

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate the Discovery of Neurotherapeutics (R21/R33)

Key Dates: 
  • Posted Date: November 3, 2015
  • Open Date (Earliest Submission Date): January 18, 2015
  • Letter of Intent Due Date(s): Not Applicable
  • Application Due Date(s): February 18, 2016; June 21, 2016; October 18, 2016; February 21, 2017; June 21, 2017; October 18, 2017 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • AIDS Application Due Date(s): Standard AIDS dates (beginning on May 7, 2016) apply by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  • Scientific Merit Review: June 2016; October 2106; February 2017; June 2017; October 2107; February 2018
  • Advisory Council Review: October 2016; January 2017; May 2017; October 2107; January 2018; May 2018
  • Earliest Start Date: November, 2016
Purpose: 

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, testing paradigms, and endpoints that will be utilized to facilitate the development of neurotherapeutics. Ideally, endpoints proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is not intended to support the development of animal and ex vivo model systems for the interrogation of disease etiology or for the identification of new drug targets. It is also not intended to support human clinical validation of model systems or pharmacodynamic markers. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

Expiration Date: 
Monday, January 8, 2018
Announcement Number: 
RFA-NS-16-013